Breaking News
Get 55% Off 0
🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% each
Unlock Stocks
Close

Baillie Gifford Investment Funds Ii Icvc-baillie Gifford Health Innovation Fund B Gbp Acc (0P0001LF93)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.594 +0.002    +0.34%
12/11 - Delayed Data. Currency in GBP
Type:  Fund
Market:  United Kingdom
ISIN:  GB00BMVLY038 
Asset Class:  Equity
  • Morningstar Rating:
  • Total Assets: 20.5M
Baillie Gifford Investment Funds II ICVC-Baillie G 0.594 +0.002 +0.34%

0P0001LF93 Overview

 
On this page you'll find an in-depth profile of Baillie Gifford Investment Funds Ii Icvc-baillie Gifford Health Innovation Fund B Gbp Acc. Learn about the key management, total assets, investment strategy and contact information of 0P0001LF93 among other information.
Category

Sector Equity Healthcare

Total Assets

20.5M

Expenses

Inception Date

Dec 15, 2020

Contact Information

Address 1 Greenside Row
Edinburgh,Scotland EH1 3AN
United Kingdom
Phone 44 0131 275 2000
Fax 44 0131 275 3999

Top Executives

Name Title Since Until
Julia Angeles Partner 2020 Now
Biography Julia Angeles is a member of the International Growth and Health Innovation Portfolio Construction Groups. She joined Baillie Gifford in 2008 and became a Partner of Baillie Gifford & Co. in 2022. Since joining Baillie Gifford, she has been part of different global and regional teams. Ms. Angeles previously worked as a Management Consultant at McKinsey & Company advising firms in Denmark, Russia and Hungary. She obtained a PhD in Economics from the University of Aarhus, Denmark, and speaks fluent Russian and Danish. Ms. Angeles has been a member of the team since 2017.
Marina Record Investment Manager 2020 Now
Biography Marina joined Baillie Gifford in 2008 as an investment analyst. She worked in a number of global teams before joining Long Term Global Growth, where she focused on analysing companies with the potential for sustained rapid growth. It was here that Marina developed an interest in healthcare, intrigued by the accelerating pace of progress in the field. She joined the Health Innovation team in January 2018 as a Portfolio Manager, to fully focus her attention on exploring the potential consequences of such progress and how Baillie Gifford can help.
Rose Nguyen Investment Manager 2020 Now
Biography Rose joined Baillie Gifford in 2013 as an investment analyst. Rose worked on various regional and global strategies before joining the Health Innovation team as a Portfolio Manager. Having observed the innovations in multiple industries, she believes that the great convergence of different technologies and sciences will ultimately transform life science. Biology can move from alchemy and randomness to become a more predictable, deterministic and repeatable science, that will give rise to a plethora of exciting investment opportunities. She joined the Health Innovation team in September 2018 at
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

0P0001LF93 Comments

Write your thoughts about Baillie Gifford Investment Funds Ii Icvc-baillie Gifford Health Innovation Fund B Gbp Acc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email